Nuvectis Pharma (NASDAQ:NVCT) Issues Quarterly Earnings Results

Nuvectis Pharma (NASDAQ:NVCT) announced its quarterly earnings data on Tuesday. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.08), Zacks reports.

Nuvectis Pharma Trading Down 0.7 %

NASDAQ NVCT traded down $0.06 during mid-day trading on Tuesday, hitting $7.31. The company’s stock had a trading volume of 13,615 shares, compared to its average volume of 118,166. The firm has a market capitalization of $141.13 million, a price-to-earnings ratio of -6.30 and a beta of 0.22. The company’s 50 day simple moving average is $6.14 and its 200 day simple moving average is $6.40. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $12.10.

Insiders Place Their Bets

In other Nuvectis Pharma news, major shareholder Marlio Charles Mosseri acquired 240,000 shares of Nuvectis Pharma stock in a transaction dated Friday, February 7th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the completion of the acquisition, the insider now directly owns 2,884,121 shares of the company’s stock, valued at $14,420,605. This represents a 9.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders have acquired 261,500 shares of company stock worth $1,300,825. Insiders own 35.78% of the company’s stock.

About Nuvectis Pharma

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.